Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of subcutaneous mezagitamab in chronic primary immune thrombocytopenia
CTR20250206Phase 3Active
- Sponsor
- Takeda
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of mezagitamab in immune thrombocytopenia (ITP), sponsored by Takeda. Started Mar 2025; status: active.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20250206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250206.